Plausible Mechanism Framework
FDA draft guidance, Feb 23 2026; comment period closed April 27 2026. Operationally extending across genes at IGI, CHOP, and Aurora Therapeutics.
Invest in Artana
Artana Bio is the upstream evidence layer of an emerging rare disease value chain. We turn fragmented biology into mechanism-defined cohorts that drug developers, foundations, and capital allocators can act on. Below is what we share at a first call.
What we share at a first call
- Incorporating as a Delaware public benefit corporation. Mission alignment legally embedded in the company structure.
- MEDopathies as the calibration cohort: ~600 patients across MED12, MED13, and MED13L. Foundation-funded, with preclinical validation across multiple lab partners. Pipeline beyond covers the full Mediator complex, chromatin and transcription regulators, and ultimately monogenic rare disease.
- Direct patient access: 200+ families across 17 countries; 124 enrolled through a major rare disease registry.
- Distribution channel via a 150-foundation neurodevelopmental disorder consortium with 40,000+ biospecimens from 4,000 individuals.
- Standards-layer partnership with an open biomedical ontology consortium covering HPO, Mondo, and DisMech.
- Scientific Advisory Board across organoids, nodal biology, structural biology, and clinical genetics.
- $3M+ in pending grants under review.
Why now
Basket trials operationalizing
Cross-gene enrollment proposals active in inborn errors of immunity (IGI-UCSF) and urea cycle diseases (CHOP). Mechanism-defined cohorts map directly to this trial architecture.
Priority Review Vouchers reauthorized
Extended through Sep 2029. Verified secondary market: Jazz $200M, Fortress/Cyprium $205M, Abeona $155M, Ipsen $158M. PRVs create downstream financial incentive for any drug developed from our cohorts.
Read up before we talk
Want context on what Artana does and how we handle clinical data before our first call?